Introduction:
Dyslipidemia, a key risk factor for cardiovascular disease, is increasingly prevalent in renal disease patients. LDL-C levels are a primary culprit in atherosclerosis. Individuals with hyperlipidemia face double the risk of heart disease. Inclisiran, a new synthetic siRNA, shows promise for dyslipidemia management, but its safety and efficacy in renal disease patients remain unknown
Methods:
We conducted a retrospective analysis of incliresin use in renal disease patients with dyslipidemia resistant to statins or experiencing statin side effects. Our goal was to evaluate the drug's effectiveness, safety, and tolerability in this population. We included all renal disease patients with uncontrolled dyslipidemia despite statin therapy or statin contraindications. Patients who declined participation or were unable to afford the injection were excluded. We monitored LDL-C, lipoprotein(a) reduction, side effects, and routine renal parameters, including renal function, urine protein excretion, and eGFR
Results:
Of 35 patients advised inclisiran therapy, 22 declined. Thirteen patients, including 8 post-transplant, 3 with nephrotic syndrome, and 2 with diabetic nephropathy and heart failure, received inclisiran. Most patients received 284 mg, while 4 received half the dose. A second dose was administered between the third and fifth month. All patients experienced significant LDL-C reduction (>60%) and lipoprotein(a) reduction (30%). No side effects were observed. One post-transplant patient with atherosclerotic peripheral vascular obstruction experienced symptom relief, and follow-up MRI angiography showed improved blood flow
Conclusions:
Inclisiran demonstrated safety in renal disease patients with dyslipidemia, without causing any adverse effects. However, further research is necessary to determine appropriate dosing for Indian patients and explore its potential applications in nephrotic syndrome, atherosclerotic cardiovascular disease, and renal transplant dyslipidemia
I have no potential conflict of interest to disclose.
I did not use generative AI and AI-assisted technologies in the writing process.